Trial Profile
Efficacy of anti-TNF agents (infliximab and adalimumab) in patients with severe and/or refractory Behcet's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
- 23 May 2016 New trial record